Wall Street Boosted by Centene’s Positive Outlook on Medicaid Plans
By Amina Niasse
NEW YORK (Reuters) – Wall Street regained confidence in Medicaid insurers after Centene announced on Friday that it anticipates increasing rates for 2026 health plans for low-income Americans, leading to strengthened profit margins.
Investor sentiment shifted positively, causing insurer shares to rise across the board. Centene saw a 5% increase in its stock price during early afternoon trading, following a 16% decline due to the company’s second-quarter loss and revised forecast. Competitors UnitedHealth, CVS Health, and Humana also experienced stock gains of 1.61%, 2.69%, and 3.45%, respectively.
All three companies are set to report their earnings next week.
During an earnings call, Centene reassured investors by stating its commitment to collaborating with states to align Medicaid plan payments with the company’s projected increased medical costs for 2026.
CEO Sarah London affirmed, “Our goal is to reprice 100% of plans.”
Medicaid insurers receive fixed payments from states for Medicaid plans, which are funded jointly with the federal government. Centene, UnitedHealth, and Elevance have all highlighted that state reimbursements for these plans have failed to cover the actual costs of care.
Concerned investors have been monitoring potential changes in Medicaid health plan designs and strategic geographic shifts by these companies to reduce healthcare service utilization.
The introduction of new work requirements for Medicaid recipients in President Donald Trump’s tax-cut and spending bill has raised concerns among some investors. They fear that healthy individuals may opt out of coverage in the coming years.
The bill mandates states to verify that certain members are working or volunteering a minimum of 80 hours per month to qualify for Medicaid coverage starting in 2027.
Following the expiration of a COVID-19 era enrollment requirement in 2023, Medicaid plans reassessed each individual’s eligibility. This led to a shift in the mix of sick and healthy participants, causing challenges for some Medicaid insurers.
Jeff Jonas, a portfolio manager at Gabelli Funds, remarked, “The Medicaid redeterminations have proven to be far more disruptive than anyone thought. The entire industry is focused on restoring margins rather than securing new contracts and memberships.”
Kevin Gade, chief operating officer at Bahl & Gaynor, suggested that more detailed data could support midyear price adjustments and rectify discrepancies in rates set by states post-pandemic.
Gade also emphasized that continued data collection over the next year would enable insurers to enhance cost management strategies and negotiate higher rates with states. He stated, “With sufficient data, you can address the issue effectively.”
(Reporting by Amina Niasse; Editing by Caroline Humer and Cynthia Osterman)
